Buy Tesamorelin Research Peptide

What is Tesamorelin?

Tesamorelin is a stabilized synthetic version of full-length GHRH (residues 1 to 44), modified to resist breakdown. It is used in animal and laboratory research as a reference tool for studying GHRH-receptor activity and growth-hormone release.

• A full-length GHRH (1-44) version modified at one end to resist breakdown
• Studied in lab pituitary preparations for GHRH-receptor binding and activity
• Studied in rodent and dog models for growth-hormone and IGF-1 activity
• Used as a reference compound in full-length GHRH research

For research use only. Not approved for human therapeutic use.

Tesamorelin (CAS 218949-48-5), also known as ThGRF(1-44)NH2, is a synthetic 44-amino acid analogue of full-length human growth hormone-releasing hormone (GHRH). With a molecular weight of 5135.86 g/mol, Tesamorelin is distinguished by the conjugation of a trans-3-hexenoic acid group to the tyrosine residue at the N-terminus, a structural modification that confers increased resistance to enzymatic degradation. Produced via solid-phase peptide synthesis, Tesamorelin acts at the GHRH receptor (GHRH-R) and is the only full-length GHRH analogue in this compound class to carry a lipid-modified N-terminal residue.

Tesamorelin occupies a distinctive position in preclinical endocrinology research as a stabilised full-length GHRH(1-44) analogue. Unlike the truncated GRF(1-29) analogues such as Sermorelin and CJC-1295, ThGRF(1-44)NH2 retains the complete 44-residue sequence of native GHRH, with the trans-3-hexenoic acid modification serving to resist dipeptidyl peptidase-IV (DPP-IV) cleavage at the N-terminus. In vitro receptor pharmacology studies in rat adenopituitary membrane preparations have examined binding characteristics and adenylate cyclase stimulation profiles of GRF analogues at the GHRH-R, characterising structural determinants of receptor engagement across full-length and truncated GRF analogue classes [1]. Published non-clinical studies in Sprague-Dawley rat and canine models have investigated Tesamorelin-mediated somatotropic axis activity, documenting GH and IGF-1 axis dynamics under controlled preclinical conditions [2], making ThGRF(1-44)NH2 a key reference compound in full-length GHRH analogue research.

Tesamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Gaudreau P, Boulanger L, Abribat T. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem. 1992 May 15;35(10):1864–9. .PubMed PMID: 15341262Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49–58. .PubMed PMID: 17214611

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Tesamorelin (CAS 218949-48-5), also known as ThGRF(1-44)NH2, is a synthetic 44-amino acid analogue of full-length human growth hormone-releasing hormone (GHRH). With a molecular weight of 5135.86 g/mol, Tesamorelin is distinguished by the conjugation of a trans-3-hexenoic acid group to the tyrosine residue at the N-terminus, a structural modification that confers increased resistance to enzymatic degradation. Produced via solid-phase peptide synthesis, Tesamorelin acts at the GHRH receptor (GHRH-R) and is the only full-length GHRH analogue in this compound class to carry a lipid-modified N-terminal residue.

Tesamorelin occupies a distinctive position in preclinical endocrinology research as a stabilised full-length GHRH(1-44) analogue. Unlike the truncated GRF(1-29) analogues such as Sermorelin and CJC-1295, ThGRF(1-44)NH2 retains the complete 44-residue sequence of native GHRH, with the trans-3-hexenoic acid modification serving to resist dipeptidyl peptidase-IV (DPP-IV) cleavage at the N-terminus. In vitro receptor pharmacology studies in rat adenopituitary membrane preparations have examined binding characteristics and adenylate cyclase stimulation profiles of GRF analogues at the GHRH-R, characterising structural determinants of receptor engagement across full-length and truncated GRF analogue classes [1]. Published non-clinical studies in Sprague-Dawley rat and canine models have investigated Tesamorelin-mediated somatotropic axis activity, documenting GH and IGF-1 axis dynamics under controlled preclinical conditions [2], making ThGRF(1-44)NH2 a key reference compound in full-length GHRH analogue research.

Tesamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Gaudreau P, Boulanger L, Abribat T. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem. 1992 May 15;35(10):1864–9. .PubMed PMID: 15341262Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49–58. .PubMed PMID: 17214611

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number218949-48-5Molecular Weight5,135.9 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTESA

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Tesamorelin (CAS 218949-48-5), also known as ThGRF(1-44)NH2, is a synthetic 44-amino acid analogue of full-length human growth hormone-releasing hormone (GHRH). With a molecular weight of 5135.86 g/mol, Tesamorelin is distinguished by the conjugation of a trans-3-hexenoic acid group to the tyrosine residue at the N-terminus, a structural modification that confers increased resistance to enzymatic degradation. Produced via solid-phase peptide synthesis, Tesamorelin acts at the GHRH receptor (GHRH-R) and is the only full-length GHRH analogue in this compound class to carry a lipid-modified N-terminal residue.

Tesamorelin occupies a distinctive position in preclinical endocrinology research as a stabilised full-length GHRH(1-44) analogue. Unlike the truncated GRF(1-29) analogues such as Sermorelin and CJC-1295, ThGRF(1-44)NH2 retains the complete 44-residue sequence of native GHRH, with the trans-3-hexenoic acid modification serving to resist dipeptidyl peptidase-IV (DPP-IV) cleavage at the N-terminus. In vitro receptor pharmacology studies in rat adenopituitary membrane preparations have examined binding characteristics and adenylate cyclase stimulation profiles of GRF analogues at the GHRH-R, characterising structural determinants of receptor engagement across full-length and truncated GRF analogue classes [1]. Published non-clinical studies in Sprague-Dawley rat and canine models have investigated Tesamorelin-mediated somatotropic axis activity, documenting GH and IGF-1 axis dynamics under controlled preclinical conditions [2], making ThGRF(1-44)NH2 a key reference compound in full-length GHRH analogue research.

Tesamorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Gaudreau P, Boulanger L, Abribat T. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem. 1992 May 15;35(10):1864–9. .PubMed PMID: 15341262Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49–58. .PubMed PMID: 17214611

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number218949-48-5Molecular Weight5,135.9 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTESA

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.